Provided by Tiger Trade Technology Pte. Ltd.

CytomX Therapeutics

5.78
+0.34006.25%
Post-market: 5.800.0200+0.35%19:48 EST
Volume:3.18M
Turnover:18.34M
Market Cap:979.34M
PE:14.36
High:6.10
Open:5.48
Low:5.48
Close:5.44
52wk High:6.35
52wk Low:0.4000
Shares:169.44M
Float Shares:113.00M
Volume Ratio:1.41
T/O Rate:2.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.4026
EPS(LYR):0.3774
ROE:66.76%
ROA:9.78%
PB:9.12
PE(LYR):15.31

Loading ...

CytomX Therapeutics Inc - Cx-2051 Phase 1 Data on Track for Q1 2026

THOMSON REUTERS
·
Jan 08

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

THOMSON REUTERS
·
Jan 08

CytomX Therapeutics Drops Amid Volume Spike, Last Down 5.4%

THOMSON REUTERS
·
Dec 19, 2025

Vera Therapeutics Appoints James R. Meyers to Board of Directors

Reuters
·
Nov 27, 2025

CytomX Therapeutics to Present at Upcoming December Investor Conferences

GlobeNewswire
·
Nov 25, 2025

Cantor Fitzgerald Remains a Buy on CytomX Therapeutics (CTMX)

TIPRANKS
·
Nov 20, 2025

Stock Track | CytomX Therapeutics Plummets 7.80% as Analysts Slash 2026 Forecasts

Stock Track
·
Nov 13, 2025

Stock Track | CytomX Therapeutics Plummets 7.80% as Analysts Slash Revenue and Earnings Forecasts

Stock Track
·
Nov 13, 2025

Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Dramatic Analyst Forecast Downgrade

Stock Track
·
Nov 13, 2025

Stock Track | CytomX Therapeutics Plunges 5.20% Pre-market Following Analysts' Dramatic Forecast Downgrade

Stock Track
·
Nov 13, 2025

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

GlobeNewswire
·
Nov 13, 2025

Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically

Simply Wall St.
·
Nov 13, 2025

CytomX Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 11, 2025

CytomX CEO Sean A. McCarthy Reports Sale of Common Shares

Reuters
·
Nov 11, 2025

Cantor Fitzgerald Remains a Buy on CytomX Therapeutics (CTMX)

TIPRANKS
·
Nov 11, 2025

Stock Track | CytomX Therapeutics Plunges 6.92% Pre-Market Following Disappointing Q3 Earnings

Stock Track
·
Nov 07, 2025

Stock Track | CytomX Therapeutics Plunges 6.92% Pre-market Following Disappointing Q3 Earnings

Stock Track
·
Nov 07, 2025

Stock Track | CytomX Therapeutics Plunges 7.16% After Q3 Earnings Miss and Revenue Shortfall

Stock Track
·
Nov 07, 2025

Cancer immunotherapy firm CytomX's Q3 revenue falls

Reuters
·
Nov 07, 2025

CytomX Therapeutics reports Q3 EPS (9c), consensus (4c)

TIPRANKS
·
Nov 07, 2025